Stock 4162 PHARMAENGINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PharmaEngine, Inc.

Equities

4162

TW0004162003

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-05-27 pm EDT 		5-day change 1st Jan Change
92.3 TWD +0.65% Intraday chart for PharmaEngine, Inc. -2.94% -12.51%
May. 02 PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors CI

Strengths

  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.22 times its estimated earnings per share for the ongoing year.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PHARMAENGINE, INC. Stock PharmaEngine, Inc.
-12.51% 412M -
MODERNA, INC. Stock Moderna, Inc.
+54.05% 58.71B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.02% 41.31B
B
LONZA GROUP AG Stock Lonza Group AG
+37.43% 39.2B
A
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.4B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.42% 26.55B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.60% 18.98B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.89% 12.51B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.40% 11.94B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.49% 12.08B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4162 Stock
  4. Ratings PharmaEngine, Inc.